Food and Drug Administration
The committee will discuss new drug application (NDA) 21-514, proposed trade name METHYPATCH (Methylphenidate) Tdp,
(Methylphenidate Transdermal System), Noven Pharmaceuticals, proposed indication for the treatment of attention deficit hyperactivity disorder (ADHD).
Noven Pharmaceuticals, Inc.
The statements contained in this document(s) are those
of the product's sponsor, not FDA, and FDA does not necessarily agree with the
FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Portions of this document have
been determined to be exempt from disclosure under the Freedom of Information
Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the screen or on the printed page.